JUNIPER PUBLISHERS- JOURNAL OF GYNECOLOGY AND WOMEN’S HEALTH Journal of Gynecology and Women’s Health-Juniper Publishers Authored by Strickland KS* Mini Review The use of adjuvant endocrine therapy (ET, e.g. tamoxifen or aromatase inhibitors: anastrozole, letrozole, exemestine) for five to ten years is the standard of care for individuals with hormone receptor positive breast cancer [ 1 ]. ET has resulted in impressive reductions in disease recurrence and mortality [ 2 ]. When taken as prescribed, these agents can reduce recurrence by 30-50% and reduce mortality by approximately one third irrespective of treatment with chemotherapy [ 2 , 3 ]. As evidence of the survival advantage of ET has mounted, taking the drug daily as direct...
Comments
Post a Comment